The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation.

doi:10.1016/j.ejmech.2020.112995

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation.

European journal of medicinal chemistry - 15 Jan 2021

He Jie, Zhou Zhihui, Sun Xin, Yang Zunhua, Zheng Pengwu, Xu Shan, Zhu Wufu

Abstract excerpt

Epidermal growth factor receptor (EGFR) is a receptor for epithelial growth factor (EGF) cell proliferation and signaling, which is related to the inhibition of tumor cell proliferation, angiogenesis, tumor invasion, metastasis, and apoptosis. Thus, it has become an important target for the treatment of non-small cell lung cancer (NSCLC). The first to the third-generation EGFR inhibitors have demonstrated...

Topics

Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Cell Proliferation
Chemistry, Pharmaceutical
ErbB Receptors
Humans
Lung Neoplasms
Molecular Structure
Mutation
Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 33243531
DOI: 10.1016/j.ejmech.2020.112995

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics